"One of the things that we want to look at long-term is how the kidney being exposed to limited durations of warm ischemia compared to no ischemia at all affects longitudinal atrophy," says Carlos Muñoz-Lopez.
In this video, Carlos Muñoz-Lopez and Steven C. Campbell, MD, PhD, highlight potential future research based on the study, “Parenchymal volume analysis to assess longitudinal functional decline following partial nephrectomy,” for which they served as the lead and senior authors, respectively. Muñoz-Lopez is a 4th-year medical student at the Cleveland Clinic Lerner College of Medicine, and Campbell is the residency program director and a professor of surgery at Cleveland Clinic in Cleveland, Ohio.
Video Transcript:
Muñoz-Lopez: One of the things that we want to look at long-term is how the kidney being exposed to limited durations of warm ischemia compared to no ischemia at all affects longitudinal atrophy. One of the things that we want to look for in the future is a good control group, and that would be a patient who has had no exposure to ischemia or the partial nephrectomy was done off clamp. In these patients, we could look at a comparator group of limited warm ischemia and see if there is a difference in their longitudinal atrophy after accounting for some of the comorbidities that we know accentuate their functional decline.
Campbell: One comment is that [in] our study we had a lot of cold ischemia and a lot of warm ischemia. But like most centers, we try to keep that warm ischemia less than 25, or certainly less than 30 or 35 minutes. So like today, when we say, well, maybe ischemia didn't do that much, that's only in the context of limited warm ischemia. If you were to get out until an hour or more of warm ischemia, you'd probably see some more negative effects.
This transcription has been edited for clarity.
Adding nivolumab to low-dose tivozanib does not improve PFS in renal cell carcinoma
July 19th 2024"While the addition of an ICI to low dose FOTIVDA did not improve PFS outcomes after prior ICI, we consider the control arm data an important, evidence-based and clinically meaningful contribution to the oncology community treating relapsed or refractory advanced RCC following front-line ICI combinations," says Michael P. Bailey.
Live bacterial supplementation may improve TKI-based treatment efficacy in kidney cancer
June 30th 2024CBM588 could be exciting in cancer treatment because of its potential to enhance the efficacy of immune checkpoint inhibitor-based treatment, improve patient outcomes, and modulate the gut microbiota in beneficial ways,” says Sumanta Pal, MD.
Pembrolizumab/lenvatinib labels updated to include KEYNOTE-B61 data in non-ccRCC
June 28th 2024"The addition of efficacy data from the KEYNOTE-B61 trial reinforces the important role of KEYTRUDA plus LENVIMA as a frontline treatment option for adult patients with advanced RCC regardless of histology," says Takashi Owa, PhD.